August 4, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — Sunridge International (OTCBB: SNDZ) said that it has signed an agreement with Ameco Medical Equipment L.L.C. for distribution rights in several Middle Eastern countries. The five-year contract, which Sunridge said it valued at over 6.5 million dollars, will start immediately.

As part of their marketing strategies, Ameco Medical will initiate a short study to involve local key opinion leaders with first hand experience with Pneumatic Trabeculoplasty, and to facilitate government reimbursement for the procedure within the region.

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. According to Sunridge, PNT is touted as a non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The two-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International.

Nevada-based Sunridge International’s Arizona-based holding company is focused on strategic acquisitions of vertically integrated companies in the private sector.

Sunridge International's wholly owned subsidiary, Ophthalmic International, is a manufacturer of medical products with offices located near Phoenix, Arizona and Rome, Italy.

OI has developed a patented 2-minute alternative treatment for glaucoma and ocular hypertension, known as Pneumatic Trabeculoplasty. OI holds worldwide patents on the PNT equipment, its disposable sterile suction ring, as well as the medical procedure itself. As well, OI has secured their 2a CE marketing approval in Europe and Canada and are currently marketing their product line through an exclusive distributor network.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html). Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[hlmsmlh] [hlthcrdp] [nwdlsldw] [ntrntnlcmpnsbsnss] [mdstsdm] [ntrntnlcmpnsbsnss] [hlthcrdp] [tchnlgy] [ftrdnwswnd]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.